Arovella Therapeutics Ltd (ASX:ALA)
A$ 0.19 0 (0%) Market Cap: 201.28 Mil Enterprise Value: 197.81 Mil PE Ratio: 0 PB Ratio: 17.27 GF Score: 36/100

Suda Pharmaceuticals Ltd at NWR Communications Investor Conference (Virtual) Transcript

Aug 03, 2021 / 04:20AM GMT
Release Date Price: A$0.047 (-7.84%)
Nadine Blayney
ausbiztv - Media

Hi there, and welcome back to the NWR Communications Investor Virtual Conference this year, of course. It's the eighth in the series. And we return to you with another great company, SUDA Pharmaceuticals. It's a biotech company that's focused on developing therapies to treat human disease.

The two focus areas for SUDA are oncology and conditions that impact the central nervous system. So it's developing its invariant natural killer T, iNKT, cell therapy platform from Imperial College London, to treat blood cancers in particular, as well as low-risk oral sprays to reformulate existing pharmaceuticals.

(Conference Instructions) Presenting today for SUDA Pharmaceuticals is Dr. Michael Baker. He is CEO and MD. Michael?

Michael Baker
SUDA Pharmaceuticals Ltd. - CEO & MD

Thanks very much, Nadine. Thanks for having me. And thanks to NWR for putting on the event. And thanks to everybody else for dialing in and taking the time. We really appreciate it. And I'm looking forward to taking you through some of what

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot